XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
Completed
NYC Health + Hospitals
Phase 4
2019-06-24
This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded,
examining the feasibility and acceptability of Buprenorphine extended-release vs. daily
sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at
community re-entry.
XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
Completed
New York University School of Medicine
Phase 4
2019-06-24
This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded,
examining the feasibility and acceptability of Buprenorphine extended-release vs. daily
sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at
community re-entry.
XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
Completed
NYU Langone Health
Phase 4
2019-06-24
This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded,
examining the feasibility and acceptability of Buprenorphine extended-release vs. daily
sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at
community re-entry.
Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films
Suspended
Wake Forest University Health Sciences
Phase 2
2022-06-01
While substance use disorders have been found to have relapse rates on part with other
chronic illnesses such as hypertension and asthma long term abstinence remains elusive for
many. The FDA has recently approve a long acting subcutaneous injectable formulation of
buprenorphine. This study aims to determine the feasibility of enrolling and randomizing
patients seeking treatment at an outpatient substance abuse clinic to buprenorphine/naloxone
films which dissolve under the tongue vs. long acting buprenorphine injection with all other
treatment aspects held constant. The study also aims to determine the effectiveness of
monthly injections of Sublocade® compared to daily oral Suboxone® SL therapy in the treatment
of moderate to severe opioid use disorder after twenty-four weeks of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
